In the News

New research from MSK develops a method for analyzing cancer cells that survive treatment for acute myeloid leukemia; identifies a transcription factor that orchestrates natural killer cell response; and finds vepafestinib is a promising therapeutic for the treatment of RET-driven cancers.

New MSK research finds a potential target against neuroendocrine transformation in lung and prostate cancers; discovers new clues about why donor T cells attack certain tissues in graft-versus-host disease; sheds light on why T cells let go of their prey; and uses CRISPR interference and dynamic cell-state transitions to discover enhancers that affect early human development.

Fourteen young scientists are poised to receive their PhD degrees from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences. Their years of dedication and training will be recognized on May 14, 2025, as part of Memorial Sloan Kettering’s 46th annual academic convocation.

A clinical trial led by doctors from MSK has found that abemaciclib — a drug already approved for certain breast cancers — can significantly slow the growth of dedifferentiated liposarcoma, a rare, aggressive soft tissue cancer.

On June 7 when Memorial Sloan Kettering opened a facility housing the novel Center for Image-Guided Interventions, a suite of endoscopy rooms, and new operating rooms for the Surgical Day Hospital.

Spend a day with the expert team in MSK's world-renowned sarcoma service.